Consistent with excellent therapeutic benefit of targeting driver gene fusion events, in December 2024, FDA approved zenocutuzumab-zbco for refractory pancreatic cancer and NSCLC that are NRG1-fusion-positive; the data cut-off for the present study occurred before this approval, but 3 events each were observed in our pancreatic cancer (0.63%) and NSCLC (0.52%) cohorts. Here, NRG1 is linked to familial pancreatic carcinoma.